Cargando…

Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae

OBJECTIVES: Ceftazidime/avibactam and meropenem/vaborbactam are preferred agents for Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) infections and are often used in combination with other agents. We aimed to characterize the synergy of combinations against KPC-Kp with var...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rogers, Tara M, Kline, Ellen G, Griffith, Marissa P, Jones, Chelsea E, Rubio, Abigail M, Squires, Kevin M, Shields, Ryan K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600568/ https://www.ncbi.nlm.nih.gov/pubmed/37901589 http://dx.doi.org/10.1093/jacamr/dlad113

Ejemplares similares

Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates
por: Rogers, Tara M, et al.
Publicado: (2023)

2183. Porin Mutations Potentiate the in Vitro Synergy of Meropenem-Vaborbactam (MVB), but not Ceftazidime-Avibactam (CZA) in Combination with Other Antibiotics against KPC-producing Klebsiella Pneumoniae (KPC-Kp)
por: Rogers, Tara M, et al.
Publicado: (2023)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing Klebsiella pneumoniae (Kp)
por: Jones, Chelsea, et al.
Publicado: (2018)

1114. Exploring bactericidal activity and emergence of resistance for carbapenem-resistant Enterobacterales (CRE) with and without Klebsiella pneumoniae carbapenemase (KPC) treated with optimized meropenem (MEM) and meropenem-vaborbactam (MEV) exposures
por: Squires, Kevin M, et al.
Publicado: (2023)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
por: Oliva, Alessandra, et al.
Publicado: (2021)

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
por: Bovo, Federica, et al.
Publicado: (2023)

Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas
por: Shamsulddin, Haider, et al.
Publicado: (2021)

High-Level Carbapenem Resistance among OXA-48-Producing Klebsiella pneumoniae with Functional OmpK36 Alterations: Maintenance of Ceftazidime/Avibactam Susceptibility
por: Lumbreras-Iglesias, Pilar, et al.
Publicado: (2021)

Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam
por: Tsivkovski, Ruslan, et al.
Publicado: (2020)

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae–Producing KPC-31, a D179Y Variant of KPC-3
por: Tiseo, Giusy, et al.
Publicado: (2021)

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
por: Nordmann, Patrice, et al.
Publicado: (2023)

1580. Colistin Potentiates the In Vitro Activity of Meropenem–Vaborbactam (M/V) Against Some, but not All KPC-producing Klebsiella pneumoniae (KPC-Kp)
por: Jones, Chelsea E, et al.
Publicado: (2019)

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020
por: Bovo, Federica, et al.
Publicado: (2022)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
por: Marino, Andrea, et al.
Publicado: (2023)

Prevalence of OmpK35 and OmpK36 porin expression in beta-lactamase and non-betalactamase- producing Klebsiella pneumoniae
por: Shakib, Pegah, et al.
Publicado: (2012)

1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2020)

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates
por: Castanheira, Mariana, et al.
Publicado: (2021)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
por: Gaibani, Paolo, et al.
Publicado: (2022)

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy
por: Arcari, Gabriele, et al.
Publicado: (2023)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
por: Bonnin, Rémy A., et al.
Publicado: (2023)

2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

2816. Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021
por: Zilberberg, Marya D, et al.
Publicado: (2023)

1238. Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States
por: Castanheira, Mariana, et al.
Publicado: (2021)

Phenotypic and Genetic Analysis of KPC-49, a KPC-2 Variant Conferring Resistance to Ceftazidime–Avibactam and Maintaining Resistance to Imipenem and Meropenem
por: Yu, Meng, et al.
Publicado: (2023)

Analysis of diverse β-lactamases presenting high-level resistance in association with OmpK35 and OmpK36 porins in ESBL-producing Klebsiella pneumoniae
por: Ejaz, Hasan
Publicado: (2022)

662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
por: Ackley, Renee, et al.
Publicado: (2019)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022)

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
por: Hackel, Meredith A., et al.
Publicado: (2017)

2443. Searching for the Optimal Treatment Regimen for Metallo-β-Lactamase Producing Enterobacteriaceae: Aztreonam Plus Ceftazidime–Avibactam vs. Aztreonam Plus Meropenem–Vaborbactam
por: Biagi, Mark, et al.
Publicado: (2018)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing bla(KPC) or bla(NDM)
por: Kuai, Junyang, et al.
Publicado: (2023)

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021)

OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo
por: Wong, Joshua L. C., et al.
Publicado: (2019)

Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?
por: Corcione, Silvia, et al.
Publicado: (2023)

Reduced Susceptibility to Carbapenems in a Klebsiella pneumoniae Clinical Isolate Producing SCO-1 and CTX-M-15 β-Lactamases Together with OmpK35 and OmpK36 Porin Deficiency
por: Venditti, Carolina, et al.
Publicado: (2020)

Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
por: Tan, Che-Kim, et al.
Publicado: (2019)

Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era
por: Bianco, Gabriele, et al.
Publicado: (2022)

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ps9m63l2jdq954rcuilgpb53ff